Human Antibody Discovery Using Transgenic Mice

Background Platform Service Advantage Related Services FAQ Online Inquiry

For over two decades, Creative Biolabs has stood at the forefront of biotechnology, pioneering innovative solutions for complex biological challenges. As a seasoned expert in the field, I have witnessed the evolution of antibody discovery, and I can confidently state that our Transgenic Mice based MemDX™ Human Antibody Discovery Services represent the pinnacle of this evolution. This cutting-edge platform is meticulously designed to generate high-affinity, fully human monoclonal antibodies with unparalleled therapeutic potential, mitigating the risks of immunogenicity and accelerating your journey from discovery to clinical success. This service is intended for research use only and not for clinical diagnostic applications.

Discuss Your Project Today

Transgenic Mice: The In Vivo Advantage for Human Antibody Discovery

Creative Biolabs has embraced the power of transgenic animal models to generate fully human antibodies that have undergone the rigorous process of in vivo affinity maturation. Our proprietary transgenic mice are genetically engineered to express human immunoglobulin genes, while their own murine antibody machinery is inactivated. When challenged with an antigen, these remarkable animals produce a robust immune response, generating a diverse repertoire of high-affinity, fully human antibodies.

Thisin vivo maturation process is critical. Within the germinal centers of the mouse's lymphoid organs, a process of somatic hypermutation and stringent selection occurs. B-cells producing antibodies with the highest affinity for the target antigen are preferentially selected and expanded, resulting in antibodies with exceptional specificity and potency. This natural optimization process is difficult to replicate with in vitro display technologies.

Fig. 1 Discovery strategy for novel, fully human mAbs and functional ADCs from immune libraries of Ig transgenic mice. (OA Literature) Fig. 1 Graphic representation of the discovery strategy for novel, fully human mAbs and functional ADCs from immune libraries of Ig transgenic mice.

Introducing the MemDX™ Platform: A Paradigm Shift in Human Antibody Discovery

At the heart of our service lies the MemDX™ platform, an integrated suite of innovative technologies designed to tackle even the most challenging aspects of antibody discovery, particularly against complex membrane proteins. The MemDX™ platform, when combined with our advanced transgenic mouse models, offers a comprehensive and powerful solution for the generation of therapeutic-grade human antibodies.

The MemDX™ platform excels in several key areas:

Antigen Design and Production: For many targets, especially multi-pass membrane proteins like GPCRs and ion channels, producing a stable and correctly folded antigen is a major bottleneck. The MemDX™ platform utilizes a range of proprietary techniques, including DNA immunization and virus-like particles (VLPs), to present these complex antigens to the immune system in their native conformation.
Advanced Immunization Strategies: We employ a variety of immunization strategies, from traditional protein-based approaches to cutting-edge DNA and mRNA immunizations. This flexibility allows us to tailor the immunization protocol to the specific characteristics of the target antigen, ensuring a robust and targeted immune response.
High-Throughput B-Cell Screening: Identifying the rare B-cells that produce the desired antibody is a critical step. The MemDX™ platform incorporates state-of-the-art B-cell screening and sorting technologies, allowing us to rapidly isolate single antigen-specific B-cells from our immunized transgenic mice.

Our Comprehensive Transgenic Mice based MemDX™ Human Antibody Discovery Service

Our service is a fully integrated, end-to-end solution that takes you from target to a panel of well-characterized, fully human antibody candidates. The process is meticulously managed by our team of experienced scientists, ensuring the highest quality and a rapid turnaround time.

Phase 1: Project Initiation and Antigen Preparation

Consultation and Strategy Development: Every project begins with a detailed consultation to understand your specific requirements, the nature of your target, and your downstream application. Our experts will work with you to design a customized project plan.
Antigen Production: Leveraging the MemDX™ platform, we will produce the optimal immunogen for your target. For challenging membrane proteins, we can utilize DNA immunization, where the genetic code for the antigen is directly introduced into the transgenic mouse, ensuring in vivo expression in its native conformation.

Phase 2: Transgenic Mouse Immunization and Immune Response Monitoring

Immunization: Our genetically engineered transgenic mice, which carry human immunoglobulin loci, are immunized using our proprietary protocols to elicit a strong and diverse B-cell response.
Titer Monitoring: We closely monitor the immune response throughout the immunization process by measuring the antibody titer in the serum of the mice. This ensures that a robust immune response has been achieved before proceeding to the next stage.

Phase 3: B-Cell Screening and Monoclonal Antibody Isolation

Isolation of Lymphocytes: Once a high antibody titer is confirmed, we isolate lymphocytes from the spleen and lymph nodes of the immunized mice.
Antigen-Specific B-Cell Screening: Using advanced flow cytometry and our proprietary B-cell screening technologies, we identify and isolate single B-cells that produce antibodies with high specificity for your target.

Phase 4: Antibody Gene Cloning, Sequencing, and Recombinant Production

Gene Recovery and Sequencing: From the isolated single B-cells, we perform reverse transcription PCR (RT-PCR) to amplify the variable regions of the heavy and light chains. These are then sequenced to determine their unique genetic code.
Recombinant Antibody Expression: The sequenced antibody genes are cloned into our high-expression mammalian vectors for recombinant production. We can produce a panel of fully human monoclonal antibodies in sufficient quantities for initial characterization.

Phase 5: Comprehensive Antibody Characterization

Binding Affinity and Kinetics: We perform detailed characterization of each antibody candidate to determine its binding affinity, and its association and dissociation rates using techniques such as Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI).
Specificity and Cross-Reactivity: We assess the specificity of the antibodies to ensure they bind exclusively to your target of interest and do not cross-react with related proteins.
Epitope Binning: For projects requiring a diverse panel of antibodies, we can perform epitope binning studies to identify antibodies that bind to different regions of the target antigen.
Developability Assessment: We conduct an initial assessment of the developability of the lead antibody candidates, evaluating their stability, solubility, and other physicochemical properties.

Advantages of Our Transgenic Mice based MemDX™ Platform

Choosing Creative Biolabs for your human antibody discovery needs provides you with a multitude of advantages:

Feature	Benefit
Fully Human Antibodies	Eliminates the need for antibody humanization, reducing the risk of immunogenicity and saving valuable time and resources.
In Vivo Affinity Maturation	Generates antibodies with high affinity, specificity, and superior developability characteristics, mimicking the natural human immune response.
Proprietary MemDX™ Platform	Enables the discovery of antibodies against even the most challenging targets, including GPCRs and ion channels.
Diverse Antibody Repertoire	Our transgenic mice produce a broad and diverse range of human antibodies, increasing the probability of finding a candidate with the desired properties.
Rapid and Efficient Workflow	Our streamlined process, from immunization to lead candidate selection, ensures a fast turnaround time without compromising on quality.
Experienced Scientific Team	With over 20 years of experience in the industry, our team of experts provides dedicated support and guidance throughout your project.

Explore Our Comprehensive Antibody Services

Creative Biolabs offers a comprehensive suite of services to support your antibody discovery and development pipeline. Explore our related services to learn how we can further accelerate your research:

Contact us today to discuss your project with one of our specialists and discover how we can help you achieve your research goals.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Why choose a transgenic mouse platform for human antibody discovery over other methods like phage display?

A: Our transgenic mouse platform leverages the power of the natural, in vivo immune system. This is a critical advantage. When our mice are immunized, the B-cells that produce human antibodies undergo a process of somatic hypermutation and affinity maturation within the germinal centers. This is an intricate biological process that selects for antibodies with not only high affinity and specificity but also superior biophysical properties, such as stability, solubility, and low polyspecificity. These "developability" characteristics are essential for a successful therapeutic candidate. While in vitro methods like phage display are powerful, they cannot fully replicate the comprehensive quality control of a living immune system, often requiring subsequent optimization steps that our platform bypasses.

Q: What is unique about the MemDX™ platform?

A: The MemDX™ platform is our proprietary, integrated technology suite specifically engineered to overcome the most significant hurdles in antibody discovery, particularly against challenging multi-transmembrane proteins like G-protein coupled receptors (GPCRs) and ion channels. Its uniqueness lies in our advanced antigen presentation strategies. We utilize DNA immunization and virus-like particles (VLPs) to present these complex proteins to the mouse immune system in their native, correctly folded conformation. This is often the key to eliciting a functional antibody response against these difficult targets, a feat that is notoriously challenging with purified recombinant proteins.

Q: How "human" are the antibodies generated from your transgenic mice?

A: The antibodies are fully human. Our proprietary transgenic mice have their endogenous murine immunoglobulin (Ig) genes functionally replaced with human Ig loci. This means the entire variable (V, D, J) and constant (C) region gene segments that encode the antibodies are of human origin. The resulting antibodies are structurally indistinguishable from those produced in humans, thereby minimizing the risk of an anti-drug antibody (ADA) response when used as therapeutics.

Q: Can you generate antibodies against a specific epitope of my target protein?

A: Yes, we can employ several strategies to enrich for antibodies targeting a specific epitope. This can involve using peptides from the desired region as part of the immunization or screening process. Additionally, by using counter-screening methods with protein variants where the epitope of interest is mutated, we can effectively isolate epitope-specific binders. We encourage you to discuss these specific requirements with our scientific team during the project design phase.

Reference

Hellmann, Ina, et al. "Novel antibody drug conjugates targeting tumor-associated receptor tyrosine kinase ROR2 by functional screening of fully human antibody libraries using Transpo-mAb display on progenitor B cells." Frontiers in Immunology 9 (2018): 2490. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1395854

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.